Naturis Cosmetics Secures ₹100 Crore ($12M) to Scale India's Cosmeceutical ODM Infrastructure

Naturis Cosmetics has raised ₹100 Crore ($12M) to scale up its production infrastructure and build out an end-to-end Original Design Manufacturing (ODM) platform in India. The investment accelerates a broader transition across the domestic personal care sector—moving contract manufacturing away from basic Original Equipment Manufacturing (OEM) models toward high-margin, IP-backed turnkey solutions. The expanded facilities give fast-moving D2C brands and pharmaceutical majors direct access to compliant, clinical-grade cosmeceutical production without the overhead of building internal facilities.

Advanced Delivery Systems & Complex Formulation Science

Formulating dermatologist-grade skincare requires strict control over active ingredient stability and micro-scale mechanics. Naturis is prioritizing three formulation technologies to handle sensitive compounds without compromising shelf-life:

Nano-Encapsulation & Lipid Nanoparticles (LNPs): Actives like pure L-Ascorbic Acid, Retinol, and Copper Peptides degrade rapidly when exposed to light or oxygen. Encapsulating them in LNPs locks in chemical stability while helping these molecules penetrate beyond the stratum corneum barrier into deeper epidermal layers.

High-Shear Micro-Fluidization: Forcing emulsions through micro-channels under intense hydraulic pressure creates uniform sub-micron droplet sizes. This structural refinement keeps formulas physically intact even during rigorous accelerated stability testing (45°C at 75% Relative Humidity).

Cold-Process Polymeric Emulsification: Eliminating heat during emulsification protects temperature-sensitive active combinations—such as high-dose Niacinamide paired with biomimetic Ceramides. The process maintains structural viscosity and eliminates phase separation without thermal stress.

These engineering capabilities allow brand partners to commercialize stable, high-efficacy products that maintain therapeutic potency throughout their shelf life.

Navigating CDSCO Frameworks and Regulatory Governance

Running a hybrid production line capable of servicing both cosmetic startups and pharmaceutical enterprises demands strict compliance with Indian regulatory frameworks. Naturis is aligning its expanded infrastructure with three core compliance standards:

Form COS-8 & Schedule M-II Compliance: Plant upgrades guarantee alignment with updated Good Manufacturing Practices (GMP) under the Cosmetics Rules 2020, securing necessary Form COS-8 manufacturing licenses.

BIS Standard Adherence: Continuous raw material screening ensures that colorants, preservatives, and active inputs remain strictly within safety thresholds defined by IS 4707 (Parts 1 & 2).

Integrated Efficacy Validation: The platform embeds Human Repeat Insult Patch Testing (HRIPT) and clinical dossier preparation directly into product development. This offers brand owners validated functional claims while steering clear of "drug" classifications under Central Drugs Standard Control Organisation (CDSCO) enforcement.

Turnkey Agility and Pharma-Cosmeceutical Convergence

The expansion directly solves two persistent bottlenecks in beauty manufacturing: prolonged product development cycles and rigid minimum order constraints.

Compressed Launch Timelines: Access to pre-validated, proprietary formulations allows D2C beauty brands to cut R&D cycles from the standard nine months to under 90 days.

Pharma-Grade Mass Scaling: Scaling output capacity beyond 100 million units annually lets pharmaceutical firms quickly launch high-margin, dermatologist-focused skin and hair care lines without sinking capital into internal facility builds.

By combining high-tech active transport systems with rigorous regulatory compliance, Naturis establishes a mature operational benchmark for India's personal care contract manufacturing sector.